earnings
confidence high
sentiment positive
materiality 0.75
Gilead Q2: revenue $7.1B, Biktarvy +9%, product sales ex-Veklury +4%; FY guidance raised
GILEAD SCIENCES, INC.
2025-Q2 EPS reported
$2.61
revenue$13,749,000,000
- Revenue $7.1B (+2% YoY), product sales ex-Veklury $6.9B (+4%); Biktarvy $3.5B (+9%).
- GAAP diluted EPS $1.56 vs $1.29 YoY; non-GAAP diluted EPS $2.01, flat YoY.
- FY2025 guidance raised: product sales $28.3-28.7B, diluted EPS $5.85-6.15, non-GAAP EPS $7.95-8.25.
- HIV sales +7% to $5.1B; Trodelvy +14% to $364M; Cell therapy -7% to $485M.
- FDA approved Yeztugo as first twice-yearly HIV prevention; MYR impairment $190M.